Lawmakers Sound Alarm On CMS’ New Risk-Based Survey

Sens. Warren and Hirono say CMS’s shortened risk-based nursing home surveys could weaken oversight and ask the agency to respond by Nov. 9.

Workforce Shortages And Medicaid Cuts Shift In-Home Care Burden To Families

A Milken Institute publication warns that home-care workforce shortages and Medicaid cuts may push more unpaid care onto families and younger people.

Build A Stronger Lower Body At Home With This 15-Minute Equipment-free Leg Workout

Fit&Well outlines a 15-minute bodyweight leg circuit with squats, lunges and glute bridges, plus modifications for beginners.

There Are Big Changes Coming To Medicaid: What You Need To Know To Protect Your Health, Home And Independence

Federal Medicaid changes include new rules for some adults and more frequent reviews for expansion enrollees. Learn the timelines and what remains uncertain.

Head Shape And Alzheimer’s; Prenatal Choline And Kids’ IQ; Aspirin And Dementia

A neurology roundup examines head shape and Alzheimer’s pathology, prenatal choline and children’s IQ, and aspirin’s possible links to dementia risk.

Monash University Study Shows Nurse-led Program Improves Midlife Dementia Risk Profiles

A Monash-led trial found improved estimated dementia risk profiles after 12 months of nurse consultations and app-based support in Australian GP clinics.

Additional Education Protects People With High Genetic Risk Of Dementia

A study of a British school-leaving-age reform found lower dementia diagnoses decades later, including among people with high genetic risk.

Live Webinar October 29: Should We Let Robots Be Doctors?

A live MedPage Today webinar on Oct. 29 will feature Ezekiel Emanuel discussing whether AI should take a more autonomous role in health care.

Why BODY20 Is Betting On Strength Training For Women

BODY20 is positioning its coached, 20-minute EMS sessions as a practical strength option as more women focus on muscle and long-term function.

‘Magic Drug’ Reduces Risk Of Death By 44% In Lung Cancer Trial

In a phase III trial, divarasib was linked to a 44% lower risk of death than older KRAS inhibitors in previously treated advanced lung cancer.